A new medication to help treat opioid use disorders and prevent overdoses
Methocinnamox (MCAM): A novel õ-opioid receptor antagonist for opioid use disorders
This study is looking at a new medication called Methocinnamox (MCAM) that might help people with opioid use disorders by providing better protection against overdoses, and it's currently being tested for safety and effectiveness before it can be used in humans.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-10763458 on NIH RePORTER |
What this research studies
This research investigates a novel medication called Methocinnamox (MCAM), which acts as an opioid antagonist. Unlike traditional treatments, MCAM has a longer duration of action and a unique way of interacting with opioid receptors, potentially offering better protection against opioid overdoses. The research includes testing MCAM's safety and effectiveness in animal models before moving to human trials. The goal is to establish MCAM as a viable treatment option for individuals struggling with opioid use disorders.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with opioid use disorders or those at risk of opioid overdose.
Not a fit: Patients who do not use opioids or are not at risk for opioid overdose may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment for opioid use disorders and improve overdose prevention.
How similar studies have performed: Previous studies with similar opioid antagonists have shown promise, but MCAM represents a novel approach that has not yet been tested in humans.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: France, Charles P — University of Texas Hlth Science Center
- Study coordinator: France, Charles P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.